Detail akcie Relmada Therapeu Rg online

Business Summary: Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Relmada Therapeutics Inc revenues was not reported. Net loss decreased 39% to $37.5M. Lower net loss reflects Research and development - decrease of 42% to $17.4M (expense), Stock-based Compensation in SGA decrease of 45% to $10.1M (expense), Stock-based Compensation in R&D decrease of 72% to $1.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.03 to -$1.18.